We demonstrate that in three cases of MC (two with immunocytoma), the IgM-RF þ component of their cryoprecipitated represents the circulating counterpart of the B-cell receptor (BCR) of the monoclonal overexpanded B-cell population. These IgMs were isolated and used to demonstrate a crossreactivity against both hepatitis C virus (HCV) NS3 antigen and the Fc portion of IgG. Epitopes were identified in a fraction of exemplary samples by using epitope excision approach (NS 31250-1334 and IgG Fc 345-355 ). The same phenomenon of crossreactivity has been shown to occur in vivo after immunization of a mouse with the NS3 1251À1270 peptide. To verify if the same reaction was also present in MC samples characterized by an oligo/polyclonal B-cell proliferation, IgM crossreactivity was tested in 14 additional samples. Five out of the 14 were reactive against HCV NS3 and 11 out of 14 were reactive against IgG-Fc peptide. The data support the role of HCV NS3 antigen in a subset of patients with MC, whereas the high frequency of the IgG-Fc epitope suggests that these B cells originate from precursors strongly selected for auto-IgG specificity. We suggest that engagement of specific BCRs by NS3 (or NS3-immunocomplex) antigen could explain the prevalence of IgM cryoglobulins in these patients
Introduction
Abnormal B-cell activation, hypergammaglobulinemia, autoantibody production and immune complex formation are common features of chronic inflammatory conditions, including persisting viral infections. Although a viral role has not yet been established, chronic B-cell stimulation is of particular interest in hepatitis C virus (HCV) infection because it has been shown to be related to the increased risk of neoplastic transformation. 1, 2 Indeed, it is documented that B-cell non-Hodgkin's lymphoma (NHL) can occur in persistently HCV-infected patients with a history of type II mixed cryoglobulinemia (MC), a chronic immune complex-mediated disease with underlying B-cell clonal proliferation. [3] [4] [5] [6] Type II MC is serologically characterized by the presence of cold-precipitable protein complexes composed of mono/oligoclonal IgM with rheumatoid factor (RF) activity, bound to oligoor polyclonal IgG. 7, 8 Morphologically it presents both bone marrow and intrahepatic multifocal B-cell lymphoid infiltrates. 5, 9 It is well documented that the vast majority of patients with symptomatic type II MC are infected with HCV and that more than 40% of the patients with chronic HCV infection have asymptomatic MC. 10, 11 The mechanisms through which HCV infection leads to RF production, MC and NHL, as well as whether these conditions are related to the lack of antiviral function, are yet unknown. Current speculation is that HCV persistence contributes to oncogenesis by greatly expanding clones of immunoglobulin secreting B cells, which depending on genetic and environmental factors, may undergo mutational events that cause the development of a malignant lymphoma. This is a similar mechanism to that hypothesized for Helicobacter pylori and mucosa-associated lymphoid tissue (MALT) lymphomas. 12 Previous studies have demonstrated that the B-cell receptor (BCR) repertoire expressed by MC-II B-cell lymphoproliferations and HCV-associated NHL is not random, with V1-69/V3-20, V3-7/V3-15, V4-59/V3-20 variable heavy (VH)/variable kappa light (VL) chain gene combinations the most represented. 4, 6 The model of an antigen-driven origin for these lymphoproliferative disorders is based upon sequence data on BCR. Several studies demonstrated infact the presence of IgV genes mutations compatible with a germinal center (GC) or post-GC derivation, a replacement/silent mutation ratio consistent with the maintenance of a functional structure of the BCR, and the presence of intraclonal heterogeneity. 4, 5, 13, 14 These notions are further strongly supported by the observation that a proportion of HCV-related MC and NHL are curable by virus eradication. [15] [16] [17] [18] [19] Conceivably, the similarity in the structure of the variable BCR region may account for selection of B cells expressing specific and common reactivity.
Understanding the nature of the B-cell-stimulating antigen has been proven to be extremely difficult. One reason relates to the difficulty in isolating expanded cells that are mostly confined to restricted areas of the bone marrow or liver. Another reason is related to the complexity of analyzing the BCR specificity of expanded cells, which are present at low concentrations among tissue-resident, nonspecific, B-cell populations and which also frequently present small differences among themselves because of the presence of an intraclonal diversity. 4, 5 Moreover, at DNA level, the bone marrow B-cell proliferation is oligoclonal in the majority of patients with type II MC. 8 A further reason is the difficulties in obtaining reliable information from comparing the amino-acid (a.a.) sequences of BCR and of antibodies of known specificity. 4 Finally, although information could be gained from the cloning of the VH and VL genes into an immunoglobulin expression vector, the strategy is cumbersome and does not guarantee that a folded protein is produced as in vivo.
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A possible way of overcoming these limitations is offered by our demonstration that the VH and VL chain a.a. sequences of the cryoprecipitable monoclonal IgM match those deduced from the DNA analysis of the IgV genes of monoclonal B cells isolated from patients with type II MC. This fact ensures that in patients with an established monoclonal pattern, the IgM component of immune complexes represents the circulating counterpart of the BCR expressed on the surface of expanded B cells and, therefore, can be exploited to identify the putative antigen involved in inducing and maintaining B-cell activation.
Materials and methods

Patients
Seventeen HCV-infected and seven HCV-negative patients with a diagnosis of MC II syndrome were considered. Patient evaluation, including diagnosis and laboratory values, is reported in Supplementary Information Table S1 . Sera obtained at diagnosis were tested for anti-HCV antibodies by enzymelinked immunosorbent assay (ELISA) (HCV 3.0, Ortho Clinical Systems, Ratitan, NJ, USA) as well as for HCV RNA (Amplicor HCV, Roche Diagnostic Systems, Branchburg, NY, USA). All patients were HIV-and HbsAg-negative. Four of them had a concomitant B-cell NHL, two a low grade immunocytoma (patients 1 and 3), one a nodal diffuse large-cell lymphoma (patient 14), and one a gastric MALT lymphoma (patient 15), the last two without bone marrow involvement. No evidence of any malignant lymphoproliferative disorder was disclosed by physical examination, thorax-and abdomen-computed tomography or by bone marrow biopsy in the remaining cases. Seven HCVnegative patients with MC syndrome were selected as negative controls (patients [18] [19] [20] [21] [22] [23] [24] . Mixed cryoglobulinemia syndrome was associated with Sjogren's syndrome in three cases (patients [20] [21] [22] , with chronic hepatitis B virus infection (HBs Ag and HBV DNA-positive in serum) in patient 18 and undifferentiated connective tissue disease in patient 23. A truly 'essential' MC syndrome was diagnosed in the remaining patients. Among HCV-negative patients, only patient 21 reported also a concomitant NHL.
GeneScan analysis of clonal B cells
Polymerase chain reaction (PCR) for the Ig GeneScanning technique (GS) were performed using previously reported VDJ FR3, specific VH family FR1, and VK fluorescent primers and PCR conditions. 8, 21 Products were subjected to capillary electrophoresis on ABI PRISM 3100. Data were elaborated with 3100 GeneScan 3.7 Software. The peak distribution ranged between 65 and 130 bp for FR3, 310 and 360 bp for FR1, and 120-180, 190-210 and 260-300 bp for VK1/VK6/VK7-JK, VK3-JK, and VK2/VK4/VK7-JK fragments, respectively.
Cloning and sequencing of variable heavyand VK molecular clones
Variable heavy and VK gene region PCR sequencing was performed as previously reported. 4 To determine the BCR sequences from oligoclonal B-cell pattern, PCR products corresponding to visualized FR1 bands (range from 310 to 360 bp) were cut off from the agarose gel and cloned using the Topo TA Cloning Kit (Invitrogen, Madison, WI, USA), according to the manufacturer's recommendations. A minimum of 20 randomly selected bacterial colonies were grown. Plasmid DNA was purified (Wizard Plus Miniprep DNA Purification System, Promega, Milano, Italy) and sequenced using Big Dye Terminators Sequencing Kits as previously described. 4 The most similar VH and VK germline genes were identified by sequence comparison with the International Immunogenetics Database program (http://imgt.cines.fr:/). Deduced a.a. sequences were determined with the Translate BLAST search protein program (http://www.ncbi.nlm.nih.gov/blast/).
Separation and purification of cryoprecipitated IgM
Mono/oligoclonal IgM component was purified from cryoprecipitate 8 by gel filtration fractionation on a Hiload Superdex 200 h 26/60 column (Amersham Pharmacia Biotech, Milan, Italy) in acetate buffer pH 4.6, followed by IgM antibody-affinity chromatography (Pharmacia Biotech, Uppsala, Sweden) as previously reported. 8 To remove contaminant IgG, we incubated the IgM-enriched fractions with protein G sepharose (Pharmacia Biotech, Uppsala, Sweden).
Fingerprinting of IgV gene rearrangement and cryoprecipitated IgM
IgM heavy and light chains were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 12% gel. In-gel trypsin digestion was performed. 8 Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-TOF) ms was performed using the Voyager-DE PRO Biospectrometry Workstation (Applied Biosystems Inc., Foster City, CA, USA), with an accelerating voltage of 20 kV. Each spectrum was acquired in a mass range between 700 and 4000 Da. Expected monoisotopic tryptic peptide masses of NS3 protein, VH and VL IgM sequences were calculated with the ExPaSy Peptide Mass Tool (http://us.expasy.org/tools). Variable heavy/variable kappa light peptides shared between BCR and IgM were searched matching the masses of peptides theoretically determined by a virtual tryptic digestion of VH and VL sequences from monoclonal B-cell DNA, and masses of peptides obtained after the tryptic digestion of heavy and light IgM chains. In the presence of an oligoclonal B-cell pattern (exemplary samples: patients 8, 10 and 13), VH/VL sequences were obtained using DNA of 20 random-picked bacterial colonies.
Binding of hepatitis C virus antigens
As a first approach, INNO-LIA HCV Ab III update ImmunoAssay (LIA, Innogenetics s.r.l., Gent, Belgium) was used with 1 mg of purified IgM. An anti-human antibody specific for IgM isotype and phosphatase-labeled was used as secondary (Kirkegaard & Perry Laboratories-Gaithersburg, MD, USA).
For ELISA assays, plates were coated with 200 ng/well of c22-3 (core protein a.a. sequence 1-120); E2 (a.a. 404-660), c33 (NS3 protein a.a. 1192-1457); C100 (NS4 a.a. 1569-1931); and NS5 (a.a. 2054-2995) HCV proteins (GmbH laboratories Reutlingen, Germany). Additionally, NS3 proteins specific for 1a, 2b, and 2c HCV genotypes (ViroGen, Watertown MA, USA) were used. A measure of 1 mg/well of purified IgM was used as primary antibody. The plates were then washed and incubated with a horseradish peroxidase-labeled goat anti-human IgM (Sigma-chemical Laboratories, St Louis, MO, USA). As negative control, the assays were performed with IgM purified from patients with cryoglobulinemia but HCV seronegative (patients [18] [19] [20] [21] [22] [23] [24] . Positive controls consisted of mouse monoclonal antibodies specific for HCV antigens (IBT-Immunological and Biochemical Testsystems GmbH-Germany, and Novocastra, Benton lane, Newcastle upon Tyne UK).
Immunoblotting
Of NS3 protein, 500 ng were subjected to 12% SDS-PAGE and transferred to Protran Nitrocellulose Transfer membrane (Schleicher-Schuell, Dassel-Germany). Single lanes were subsequently incubated with 1 mg of purified IgM, from single patients as primary, and with anti-human IgM peroxidase-labeled as secondary antibodies (Sigma-chemical Laboratories, St Louis, MO, USA). Bands were revealed with a chemiluminescent substrate (ECL Western blot detection reagent, Amersham, API, Indianapolis, IN, USA) followed by autoradiography (Hyperfilm ECL Amersham API, Indianapolis, IN, USA). IgM purified from patient 20 and an anti-NS3 antibody (Novocastra, Benton lane, Newcastle upon Tyne, UK) were used as controls.
Rheumatoid factor activity
Rheumatoid factor activity was measured by ELISA assay (Sanquin, Central laboratory of the Netherlands Red Cross, Amsterdam, The Netherlands), following the manufacturer's instructions but using 1 mg of IgM, instead of patient's serum, as primary antibody. Rheumatoid factor activity was calculated in UI/mg of IgM as 4200,4100,412 and o12 UI.
It is known that RF activity is mainly directed against the Fc region of IgG 22, 23 in patients with rheumatoid arthritis; however, the target is unknown in the case of MC. To test IgM affinity toward the Fc portion of IgG, an ELISA assay was performed using purified human IgG Fc (MP Biomedical, Irvine, CA, USA) as coating antigen. The primary antibody consisted of cryoprecipitated IgM, whereas the secondary consisted of an antihuman IgM HRP-conjugate. As positive control, we used as primary an anti-human IgG Fc-specific HRP-conjugate antibody (Sigma-chemical Laboratories, St Louis, MO, USA).
To confirm the recognition of epitope Fc 345À355 , 200 ng of synthetic peptide (IgTech, Paestum, Salento, Italy) were tested in ELISA as described above.
Competitive rheumatoid factor-NS3 enzyme-linked immunosorbent assay test
By ELISA, in two exemplary oligo/policlonal IgM samples, which showed an IgG-NS3 crossreactivity (patients 5 and 7), and in B3-18 hybridoma, NS3 antigen was used as a competitive inhibitor of IgM RF binding. Binding to the IgG-Fc in the presence of excess of fluid phase concentrations of NS3 was expressed as the percent binding of IgM to the same IgG-Fc in the absence of NS3 antigen. Serial dilutions, 0-20 nmol of NS3, were incubated with the IgM at concentrations optimal for IgGFc binding. The mixtures were then added to IgG-Fc-coated wells. Wells were washed, and the amount of RF bound quantified. The same competitive ELISA assay was performed using NS3 protein as coating antigen and IgG-Fc as inhibitor.
Epitope excision approach
Epitope excision experiment was performed as described. 24 Briefly 0.2 g of CnBr-activated 4B sepharose beads (Amersham Pharmacia Biotech, Milan, Italy) were suspended in 1 mM HCl and pipetted into reaction columns (Handee Mini-Spin Columns, Pierce Biotechnology, Rockford, USA). Of purified IgM, 30 mg were added to the beads and incubated for 2 h at room temperature. The beads were washed with 0.1 M Tris-HCl (pH 8), then equilibrated in PBS and incubated for 2 h at room temperature with antigen (sample) or without antigen (blank). Antigens were HCV NS3 1b (Immunological and Biochemical Testsystems GmbH laboratories), HCV NS3 2b/2c (ViroGen, Watertown MA, USA) or human IgG Fc (ICN Pharmaceuticals, Aurora, OH, USA). Trypsin digestion was carried out overnight at 371C in 50 mM NH 4 HCO 3 buffer (pH 7.8) with an enzyme: substrate ratio of 1:20. Following proteolysis, the beads were washed with digestion buffer, and the eluate was concentrated under vacuum and then subjected to Zip Tip cleanup (Millipore s.p.a., Milano, Italy) before MALDI-TOF analysis. Affinity bound peptides were dissociated from IgM by addition of 0.1% trifluoroacetic acid (TFA) and the eluate was subjected to MALDI-TOF analysis.
Hybridoma production
Of NS3 peptide VLVLNPSVAATLGFGAYMSK (IgTecH, Paestum, (SA), Italy), 50 mg were used to immunize a BALB/c mouse. Mouse spleen cells were fused with NS1 myeloma cells. The cells were then diluted in 20% calf serum Dulbecco's modified Eagle's medium supplemented with HAT medium (Sigmachemical Laboratories, St Louis, MO, USA), and then seeded into microtiter plates. After 3 weeks, ELISA, using NS3 as coating antigen, was employed to test supernatants. Isotype determination of the positive clone (called B3-18) was performed with Mouse Typer Sub-Isotyping kit (Bio-Rad, Milano, Italy). B3-18 was purified using a Hi Trap IgM purification column.
Statistical methods
Significant tests for qualitative parameters were computed by Fisher's exact test. As the data were not normally distributed, nonparametric statistic tests were used. The Wilcoxon rank-test was used to compare the distribution of cryocrit percentage and serum RF concentration between two groups of patients (i.e., NS3-positive IgM and NS3-negative IgM patients). 25 The results were considered to be statistically significant when Pp0.05.
Results
Identity between BCR of monoclonal B cells and cryoprecipitated IgM
To begin searching for a BCR ligand potentially involved in inducing and maintaining clonal B cell proliferation, two experiments were performed in parallel. First, IgH VDJ gene rearrangement from bone marrow specimens of patients with type II MC was examined by PCR. A polyclonal pattern was observed in seven subjects (samples 7, 9, 11, 14-17), an oligoclonal pattern in seven subjects (samples 4, 5, 6, 8, 10, 12, 13) and a frank monoclonal pattern in three subjects (samples 1-3). Nucleotide VH and VL sequences were deposited in the NCBI GenBank (AF301518, AY703067, AY703068, AY704914, AY703069, AY703066). In the second experiment, purified IgM from serum cryoprecipitates were analyzed by MALDI-TOF mass spectrometry. In the three patients with a B-cell monoclonality, the peptide mass fingerprinting of IgM matched the fingerprinting of BCR sequences as generated by the Peptide Mass Expasy Tool (Table 1) . Moreover, peptides attributed to both the patient variable heavy and light chains carry several replacement mutations with respect to the most similar germline
genes and this result corroborates the identity between variable region of BCR and that of cryoprecipitated IgM. In three HCVinfected patients tested by fingerprinting and displaying a restricted oligoclonal-B-cell pattern (samples 8, 10 and 13), although intraclonal diversity may be present 4 and IgM is often oligoclonal, 8 some peptides shared between some BCRs and cryoprecipitated IgMs have been found. Table 1 reports a specific peptide, found in sample eight, which showed a mutation shared between the BCR and the IgM. Other peptides were identical to germ line; thus, these were not reported.
Comparison of BCR/IgM fingerprinting from polyclonal B-cell samples was not performed owing to the too high number of Bcell clones that should be analyzed to obtain an adequate information. In these cases, it is possible that several bone marrow B-cell clones contribute to the oligo/policlonal production of these IgMs, and/or, that antibody secreting cells (ASC) responsible of the cryoprecipitable IgM component are confined in a compartment different from bone marrow. This concept is supported by the demonstration that under chronic inflammatory conditions, B cells bearing antigen-specific receptors can be stimulated to proliferate and differentiate into ASC within ectopic sites, 26, 27 including the germinal centers of intraportal lymphoid liver follicles in HCV infection. 9 Nevertheless, by analogy to that we showed for the bone marrow with monoclonal B cell, cryoprecipitated IgMs should represent the counterpart of ectopic ASCs.
Monoclonal B cell of chronically hepatitis C virusinfected patients bind hepatitis C virus NS3 protein
By LIA test, cryoprecipitated IgM from two out of the three patients with a monoclonal B-cell pattern and 4/14 HCVpositive patients with an oligo-polyclonal pattern showed a weak reactivity against HCV-NS3 protein. Enzyme-linked Only specific patient's IgV peptides are reported, mutations with respect the most similar germline gene are evidenced in bold face. Identify by MALDI-TOF mass spectrometry VK peptides from patient 8 and both VH and VK peptides from patient 10 and 13 are unmutated with respect the most similar germline genes. Thus, they are not reported. Abbreviation: VH, variable heavy.
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immunosorbent assay (Figure 1a ) and Western blot ( Figure 1b ) were used to confirm reactivity against NS3. The E2, core, NS4A, NS4B and NS5 HCV antigens were not bound by the same IgM. Furthermore, there was no signal visible when IgM purified from seven selected HCV-negative patients with type II MC were used. As NS3 protein immobilized in the LIA strip is specific for the 1b HCV-genotype, an additional ELISA assay was carried out with recombinant NS3 protein specific for the patient's HCV genotype. Two additional patients (patients 3 and 15) were positive with HCV-NS3 2b and 2c genotypes, respectively ( Figure 1a ). NS3 reactivity is related to higher production of cryoglobulins (P ¼ 0.01 Wilcoxon test) but not to the value of RF (n.s. Wilcoxon test, Figure 1a ).
Monoclonal B cell of chronically hepatitis C virusinfected patients shows rheumatoid factor activity
As IgMs are often polyreactive and cryoprecipitated IgMs usually have RF activity, we verified whether IgM showed reactivity against human IgG. All samples showed RF activity by standard ELISA (Figure 2a) . Rheumatoid factor activities positively correlate with serum RF concentrations, Fisher exact test P ¼ 0.03 (Figure 2a ).
Monoclonal IgM of chronically hepatitis C virusinfected patients recognize distinct epitopes
To verify if the crossreactivity against NS3 and IgG was due to mimicry between these two antigens, we attempt to define the NS3 and IgG epitopes recognized by IgM. The epitope analysis was performed only for patients 1, 3, 5 and 7, from whom it was possible to obtain sufficient IgM for the analysis. All of these IgM recognized the Fc portion of IgG in ELISA (Figure 2b and c) . These were therefore incubated with either polyclonal human-IgG Fc fragment or genotype-specific HCV-NS3 protein.
The results for NS3 show three different sets of affinity bound peptides: 2038.2 Da (for patient 1) (Figure 3a-e Table S2 ). Interestingly, IgM bound peptides are adjoining segments localized in the helicase domain of the NS3 protein ( Figure 3e ) in a region exposed to the solvent (Figure 3d ). In contrast, for the IgG-Fc, the mass of the affinity bound peptide (1286.7 Da) is unique for all the samples tested. This mass matched (Mascot Data Base) the monoisotopic mass of the Fc 345À355 EPQVYTLPPSR sequence of the CH3 region of human IgG 1 , IgG 2 and IgG 3 (Figure 4a ). Moreover, we confirmed by ELISA that the synthetic peptide, Fc 345À355 , reacted with 13/17 IgM tested (Figure 4b ).
B3-18 hybridoma recognized Fc 345À355 peptide
To verify the hypothesis that an anti-NS3 IgM would be reactive against an IgG-Fc antigen, we used the synthetic peptide corresponding to the NS3 epitope recognized by IgM from patient 1, to immunize a BALB-c. A positive ELISA clone (B3-18) was selected, expanded and resulted in an IgMk antibody. This antibody, as ascertained by epitope excision and ELISA (Figure 5a ), identified the same Fc 345À355 EPQVYTLPPSR peptide, and thus possesses the same dual reactivity as IgM from patient 1.
NS3 inhibition of IgM-rheumatoid factor binding to IgG
Competitive RF-NS3 ELISA test demonstrated that NS3 partially inhibited the IgM binding of IgG-Fc in both the exemplary oligo/ policlonal samples tested (samples 5 and 7), as well as in the B3-18 hybridoma (Figure 5b) . Moreover, IgG-Fc-binding inhibition was achieved by preincubation with lower NS3 concentrations for B3-18 than for samples 5 and 7. IgG-Fc fragment completely inhibited the IgM binding to NS3 for both samples 5 and 7, whereas only partially inhibited B3-18. 
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Discussion
It is currently believed that HCV is frequently the etiologic agent for type II MC, an autoimmune disease that may evolve into a malignant lymphoma. 4, 28, 29 Analysis of the BCR sequences in HCV NHL suggested that chronic antigenic stimulation, due to HCV persistence, could drive these lymphocyte proliferations in a manner similar to that hypothesized for Helicobacter pylori and MALT lymphomas. 12 Nevertheless, sequence data are insufficient to draw conclusions on BCR specificity. 4 In the present study, we found that the BCRs of bone marrow monoclonal B cells share the same antigen-binding fragment (Fab) with the cryoprecipitated IgM of the same patient. In some cases, we could demonstrate the same identity in patients displaying an oligoclonal B-cell pattern. The evidence that IgM Our data showed that cryoprecipitated IgM demonstrate a weak reactivity against the helicase domain of the NS3 protein in all patients with a bone marrow monoclonal B-cell pattern and in a consistent portion (5/14, 36%) of HCVrelated MC patients. Neither were the E2, core, NS4A, NS4B and NS5 HCV antigens bound by the same IgM nor was a signal visible using IgM purified from seven selected HCVnegative patients with type II MC. Moreover, NS3 positivity was associated with a higher production of cryoglobulins (P ¼ 0.01).
The finding that IgMs of a fraction of patients from our series (nine out of 17 subjects) were negative against NS3 or any other HCV antigen could be due to a loss of HCV specificity during the evolution of lymphoproliferative disease, as in HP-MALT lymphoma. 12 Alternatively, the positive signals may be hidden by the high diversity of HCV sequences. 30, 31 It is known that during HCV infection, NS3 can induce an important humoral and cellular immune response. [32] [33] [34] [35] [36] [37] Nevertheless, the structural details about the antigen presenting cells and the B-cell epitope recognition in vivo are still unknown. By epitope excision approach, we identified epitopes within the NS3 1238À1279 region. Interestingly, the same fragment has been previously indicated as one of the two immunodominant regions for B cells (AA 1250-1334; AA 1359-1449) . [32] [33] [34] Additionally, we found that all IgMs present reactivity against human IgG, in agreement with our previous results from HCV-MC related NHL. 4 By epitope excision approach, a unique peptide, Fc 345À355 EPQVYTLPPSR, was identified as an epitope and reactivity was confirmed using this synthetic peptide in ELISA. The Fc 345À355 peptide is localized on the CH3 domain of IgG and it is part of the dimeric interface of the immunoglobulin. Its sequence is conserved among the different IgG classes, except for IgG 4 , which has a single mutation (EPQVYTLPPSQ). Although the high diversity of the NS3 and Fc epitopes seems to exclude molecular mimicry, overall data suggest that IgM antibodies against the NS3 1238À1279 domain have crossrecognition for Fc 345À355. To confirm this crossreaction, we immunized a mouse with the NS3 1251À1270 peptide, identified as an NS3 epitope in patient 1. Consistent with the idea of crossreactivity, the hybridoma B3-18 produced an IgMk antibody, showing the same double RF IgG-Fc 345À355 and NS3 1251À1270 reactivity as IgM from patient 1. Moreover, NS3 antigen was demonstrated to inhibit IgM binding to IgG-Fc, and vice versa, IgG-Fc inhibited binding of NS3 in competitive ELISA test. However, B3-18 had a lower affinity with Fc fragment than with NS3. Conversely, the affinities of samples 5 and 7 for IgG-Fc were higher than that for NS3, indicating that a higher specificity toward IgG-Fc than toward NS3 during the evolution of lymphoproliferative disease may be possible.
This result is important because it reproduces in vivo the crossreaction observed in the MC patient and demonstrates, for the first time, a direct crossreactivity of IgM for the HCV NS3 1238À1279 and the IgG-Fc 345À355 domain. Therefore, we suggest that the T-cell mediated process of clonal selection and somatic mutation, shown in HCV-related lymphoproliferation 5 and probably induced by HCV-NS3, could lead to the production of RF autoantibodies. A subsequent increase of RF activity may represent an advantageous phenomenon for some infective agents as it is present in the course of other microbial infections with B-cell expansion (e.g. as a consequence of staphylococcus, HSV-1, HSV-2, varicella-zoster, CMV and EBV infection [38] [39] [40] ). It has recently been reported that HCV core and NS3 proteins trigger inflammatory cell activation via the pattern recognition receptor TLR2. 41 Thus, we hypothesized that in HCV infection, NS3 HCV-molecules, able to crosslink some BCR (directly and/ or by Fc-immunocomplex mediation), could engage a Toll-like receptor and induce B-cell stimulation 42, 43 and IgM-RF þ production. Consequently, data herein reported provide the rationale for evaluation of the NS3 1238À1279 domain as a target for new immunotherapeutic approaches. project LR 11/2003 and by Società Italiana di Reumatologia. 
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